GEN Exclusives

More »

Feature Articles

More »
Sep 1, 2010 (Vol. 30, No. 15)

Nanotechnology Draws Closer to a Clinical Debut

T-Cell Based Delivery Systems and New Imaging Options Push Field Forward

  • Click Image To Enlarge +
    Scientists at InCellerate are working on a high-throughput microelectroporation device called HiTMeD. T cells generated from the device reportedly can respond more rapidly and more robustly as drug-delivery vehicles and also have potential as a tumor-specific, adoptive immunotherapy.

    Nanotechnology is combining with T-cell biology to produce diagnostics and therapeutics that evade the immune system and deliver localized therapeutic payloads, which, through their tight targeting, minimize adverse side effects.

    At TechConnect World’s recent “Nanotech” conference and expo in Anaheim, industry and academic researchers elaborated on the advances that are driving nanotechnology toward  the clinic, including T-cell based delivery systems, the ability to design nanoparticles’ function and morphology, and new imaging options.

    InCellerate, a new company formed by Laurence J. N. Cooper, M.D., Ph.D., director of pediatric cell therapy at M.D. Anderson Cancer Center, has been working on a high-throughput microelectroporation device—called HiTMeD—to electro-transfer RNA species to redirect T-cell specificity.

    The device is also being designed to electro-transfer gold nanoparticles that can be functionalized to enhance T-cell biology. This combination generates T cells that can respond more rapidly and more robustly as a drug-delivery vehicle, thus having potential as a tumor-specific, adoptive immunotherapy.

    “We see T cells as a vehicle for targeted delivery of nanoparticles to tissue sites,” Dr. Cooper said. Typically, the reticular endothelial system filters out infused nanoparticles. Wrapping the nanoparticles in T cells thwarts that. And, because chimeric antigen receptor (CAR) expression from mRNA will be temporary, InCellerate developed HiTMeD to make multiple infusions of these modified T cells practical.

    T cells endogenously express a panel of receptors that orchestrate their ability to home to disease. InCellerate’s microelectroporation device essentially pokes holes in T cells so genes and/or nanoparticles can be inserted, thus turning the T cells into therapeutic or diagnostic vectors.

    “This is different from therapy in which therapeutic genes are introduced using viruses,” Dr. Cooper stressed. The introduced gene enhances specificity to better eliminate malignant cells, while the nanoparticles add potency or imaging properties.

    In targeting lung cancer, Dr. Cooper and his colleagues have introduced a CAR into  T cells. This antigen receptor recognizes the CD19 molecule expressed on the cell surface of B-cell malignancies. Introducing the CAR as mRNA avoids integration into the T-cell chromosome and “avoids the potential genotoxicity associated with vector and transgene integration. In addition, the high-throughput capacity overcomes the expected transient CAR expression, as repeated rounds of electroporation can replace T cells that have lost transgene expression.”

    HiTMeD can electroporate 2x108 cells within 10 minutes, ex vivo, according to Dr. Cooper. In tests, up to 80% of the primary T cells expressed the CD-19-specific CAR. This is at least a 10-fold improvement over other technologies, he added.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?